A Phase 3 Global Double-Blind Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy

Go Back to All Clinical Trials

A Phase 3 Global Double-Blind Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy

Brief description of study

The purpose of this study is to evaluate the safety of ION-682884 and determine if it can help people with cardiomyopathy.ION-682884 is an investigational drug. “Investigational” means that ION-682884 is not approved for use in any settings outside of clinical research studies like this one and is considered experimental. ION-682884 reduces the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in your blood may reduce the amount of amyloid deposits in your body and may keep your cardiomyopathy from getting worse over time. However, it is not known if ION-682884 will help the cardiomyopathy.

Clinical Study Identifier: s19-01758

ClinicalTrials.gov Identifier: NCT04136171

Principal Investigator: Alex Reyentovich.

Other Investigators: Maureen Coletta Geary, Jose A Alvarez-Cardona, Tajinderpal Saraon.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies